Results by division in FY 24 :
- Sales and distribution of products : 108.5 m$ (- 6 %)
Profit : 16 $ vs 30 m$.
- Medical consultation and service fees : 15.4 m$ vs 1.6 m$. Increase due to the acquisition of Doctors on Demand
Loss : 3.2 m$ vs loss of 2.8 m$.
- Corporate costs : 9.5 m$ vs 13.6 m$.
So, their main problem in FY 24 was their sales and distribution of products division where they had a sales decrease (+ 7 % for volume), decrease of gross margin and probably cost increase. Main driver was the price decrease (average selling price decrease by 9 % for SKU offered on Canview).
I understand that they can probably decrease their cost basis in FY 25, due in particular to several one offs in FY 24 (transaction costs, legal cost, restructuration costs). What is more surprising : the company targets a 10 % organic growth for revenues. I wonder what can drive such a growth, in particular if cannabis prices continue to decrease (?).
Add to My Watchlist
What is My Watchlist?
